Oxford Biomedica 관리

관리 기준 확인 2/4

Oxford Biomedica CEO는 Frank Mathias, Mar2023 에 임명되었습니다 의 임기는 1.67 년입니다. 총 연간 보상은 £ 520.00K, 88.1% 로 구성됩니다. 88.1% 급여 및 11.9% 보너스(회사 주식 및 옵션 포함). 는 € 101.87K 가치에 해당하는 회사 주식의 0.019% 직접 소유합니다. 101.87K. 경영진과 이사회의 평균 재임 기간은 각각 1.2 년과 3.7 년입니다.

주요 정보

Frank Mathias

최고 경영자

UK£520.0k

총 보상

CEO 급여 비율	88.1%
CEO 임기	1.7yrs
CEO 소유권	0.02%
경영진 평균 재임 기간	1.2yrs
이사회 평균 재임 기간	3.7yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Frank Mathias 의 보수는 Oxford Biomedica 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Jun 30 2024	n/a	n/a	-UK£142m
Mar 31 2024	n/a	n/a	-UK£150m
Dec 31 2023	UK£520k	UK£458k	-UK£157m

보상 대 시장: Frank 의 총 보상 ($USD 653.01K ) German 시장에서 비슷한 규모의 회사에 대한 평균보다 낮습니다( $USD 1.03M ).

보상과 수익: Frank 의 보상을 회사 성과와 비교하기에는 데이터가 부족합니다.

CEO

Frank Mathias (62 yo)

1.7yrs

테뉴어

UK£520,000

보상

Dr. Frank Mathias is Chief Executive Officer and Director of Oxford Biomedica plc from March 27, 2023. Dr. Mathias was the Chief Executive Officer of Rentschler Biopharma SE from April 2016 until March 202...

리더십 팀

이름	위치	테뉴어	보상	소유권
Frank Mathias	CEO & Director	1.7yrs	UK£520.00k	0.019% € 101.9k
Lucinda Crabtree	CFO & Director	less than a year	데이터 없음	데이터 없음
Thierry Cournez	Chief Operating Officer	1.1yrs	데이터 없음	데이터 없음
Sophia Bolhassan	Head of Investor Relations	no data	데이터 없음	데이터 없음
Natalie Walter	General Counsel & Company Secretary	5.5yrs	데이터 없음	데이터 없음
Lisa Doman	Chief People Officer	2.6yrs	데이터 없음	데이터 없음
Kyriacos Mitrophanous	Chief Innovation Officer	less than a year	데이터 없음	데이터 없음
Kati Hudson	Head of Intellectual Property and Contracts	no data	데이터 없음	데이터 없음
Sebastien Ribault	Chief Business Officer	2yrs	데이터 없음	데이터 없음
Mark Caswell	Site Head of UK Operations	1.3yrs	데이터 없음	데이터 없음
Stephanie Colloud	Site Head & GM of France Operations	less than a year	데이터 없음	데이터 없음
Sabine Sydow	Chief of Staff	less than a year	데이터 없음	데이터 없음

1.2yrs

평균 재임 기간

51yo

평균 연령

경험이 풍부한 관리: OXOA 의 관리팀은 경험 (평균 재직 기간 1.2 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Frank Mathias	CEO & Director	1.7yrs	UK£520.00k	0.019% € 101.9k
Lucinda Crabtree	CFO & Director	less than a year	데이터 없음	데이터 없음
Frederic Doliveux	Non-Executive Chair	4.4yrs	UK£225.00k	0.35% € 1.9m
William Langston	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Peter Stern	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Krystof Bankiewicz	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Leone Patterson	Independent Non-Executive Director	1.5yrs	UK£87.00k	0.012% € 63.4k
Heather Preston	Independent Non-Executive Director	6.7yrs	UK£140.00k	0.017% € 93.2k
Dame Davies	Senior Independent Director	3.7yrs	UK£73.00k	0.00095% € 5.1k
Stuart Henderson	Independent Vice Chair	8.4yrs	UK£85.00k	0.010% € 55.3k
Robert Ghenchev	Non-Executive Director	5.4yrs	데이터 없음	데이터 없음
Namrata Patel	Independent Non-Executive Director	2.6yrs	UK£65.00k	0.0087% € 46.7k

3.7yrs

평균 재임 기간

62yo

평균 연령

경험이 풍부한 이사회: OXOA 의 이사회는 경험(평균 재직 기간 3.7 년)으로 간주됩니다.

Oxford Biomedica 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Oxford Biomedica plc Announces Board Changes

Oxford Biomedica plc Appoints Lucinda (Lucy) Crabtree as Board Member

Oxford Biomedica plc Announces Appointment of Laurence Espinasse as Non-Executive Director

Oxford Biomedica plc Announces CFO Changes, Effective from September 2, 2024

Oxford Biomedica plc, Annual General Meeting, Jun 24, 2024

Oxford Biomedica plc Announces Board Changes

Recent updates

Oxford Biomedica plc Announces Board Changes

First half 2024 earnings released: UK£0.31 loss per share (vs UK£0.50 loss in 1H 2023)

Oxford Biomedica plc Provides Earnings Guidance for the Full Year 2024

Oxford Biomedica plc Appoints Lucinda (Lucy) Crabtree as Board Member

Oxford Biomedica plc Provides Earnings Guidance for the First Half of 2024 and Reiterates for the Full Year 2024

Oxford Biomedica plc Announces Appointment of Laurence Espinasse as Non-Executive Director

Oxford Biomedica plc Announces CFO Changes, Effective from September 2, 2024

Oxford Biomedica plc, Annual General Meeting, Jun 24, 2024

Oxford Biomedica plc Reiterates Earnings Guidance for the Year 2024

Full year 2023 earnings released: UK£1.63 loss per share (vs UK£0.41 loss in FY 2022)

Oxford Biomedica plc Announces Board Changes

Oxford Biomedica plc to Report Fiscal Year 2023 Results on Apr 29, 2024

New minor risk - Shareholder dilution

Oxford Biomedica plc (LSE:OXB) completed the acquisition of additional 3.2% stake in ABL EUROPE S.A.S. from TSGH.

Oxford Biomedica plc Provides Business Update

Oxford Biomedica plc (LSE:OXB) entered into a sale and purchase agreement to acquire ABL EUROPE S.A.S. from TSGH for €15 million.

New major risk - Share price stability

Non-Executive Chair recently bought €115k worth of stock

Oxford Biomedica Talks to Buy ABL Europe

First half 2023 earnings released: UK£0.50 loss per share (vs UK£0.27 loss in 1H 2022)

Oxford Biomedica plc Provides Revenue Guidance for the Year 2023 and 2024

Oxford Biomedica plc to Report First Half, 2023 Results on Sep 20, 2023

Oxford Biomedica plc Launches TetraVectaTM - the Next Generation Lendediviral Vector System

Oxford Biomedica plc, Annual General Meeting, Jun 23, 2023

Oxford Biomedica plc, Annual General Meeting, Jun 23, 2023

Full year 2022 earnings released: UK£0.41 loss per share (vs UK£0.23 profit in FY 2021)

High number of new directors

Oxford Biomedica plc Announces Siyamak Rasty Will Not Be Standing for Re-Election

Oxford Biomedica Appoints Frank Mathias as Board Director

High number of new directors

Kadans Science Partner B.V. agreed to acquire Windrush Court facility from Oxford Biomedica plc (LSE:OXB) for £60 million.

First half 2022 earnings released: EPS: UK£0 (vs UK£0.22 in 1H 2021)

Oxford Biomedica plc Provides Earnings Guidance for the Second Half of 2022

Oxford Biomedica plc to Report First Half, 2022 Results on Sep 15, 2022

Oxford Biomedica plc(LSE:OXB) dropped from FTSE 350 Index (GBP)

Investor sentiment deteriorated over the past week

Oxford Biomedica Notes Announcement That FDA Has Lifted Clinical Hold on Homology Medicines' Phenix Trial

John Dawson Has Steps Down from the Oxford Biomedica Plc's Board of Directors

Full year 2021 earnings released: EPS: UK£0.23 (vs UK£0.078 loss in FY 2020)

High number of new directors

Interim CEO & Chairman recently bought €412k worth of stock

Full year 2021 earnings released: EPS: UK£0.23 (vs UK£0.078 loss in FY 2020)

Oxford Biomedica plc Provides Revenue Guidance for the Year 2022

Oxford Biomedica plc Announces the Appointment of Namrata P Patel as Independent Non-Executive Director

Oxford Biomedica plc to Report Fiscal Year 2021 Results on Apr 20, 2022

Investor sentiment deteriorated over the past week

Oxford Biomedica plc, Annual General Meeting, Mar 08, 2022

Investor sentiment deteriorated over the past week

Oxford Biomedica plc announced that it expects to receive £50.000001 million in funding

First half 2021 earnings released: EPS UK£0.22 (vs UK£0.087 loss in 1H 2020)

Non-Executive Director Andrew John Heath has left the company

Full year 2020 earnings released: UK£0.078 loss per share (vs UK£0.22 loss in FY 2019)

Oxford Biomedica plc Provides Earning Guidance for the Year 2021

Oxford Biomedica plc to Report Fiscal Year 2020 Results on Apr 15, 2021

New 90-day high: €12.24

Non-Executive Director has left the company

Oxford Biomedica plc Announces Board Changes

Oxford Biomedica plc(LSE:OXB) dropped from FTSE All-Small Index (GBP)

New 90-day high: €10.39

Independent Non-Executive Director recently sold €430k worth of stock

Oxford Biomedica plc Appoints Sam Rasty as Non-Executive Director

New 90-day high: €9.99

Oxford Biomedica plc and PhoreMost Enters Gene Therapy Collaboration

Oxford Biomedica plc Notes Axovant’S Positive Six-Month Follow-Up from Second Cohort of Sunrise- PD Phase 2 Trial of Axo-Lenti-Pd

First half earnings released

Papyrus Therapeutics Inc. Signs Research Collaboration With Oxford Biomedica plc

Oxford Biomedica plc to Report First Half, 2020 Results on Sep 17, 2020

New 90-day high - €9.92

CEO 보상 분석